(Q50571426)

15 March 2018

title

Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C. (English)

1 reference

15 March 2018

1 reference

1 reference

10

Takashi Kumada

1 reference

15 March 2018

Hidenori Toyoda

9

Hidenori Toyoda

1 reference

15 March 2018

Masatoshi Ishigami

6

Masatoshi Ishigami

1 reference

15 March 2018

Hidemi Goto

11

Hidemi Goto

1 reference

15 March 2018

Yoshiaki Katano

2

Yoshiaki Katano

1 reference

15 March 2018

Isao Nakano

7

Isao Nakano

1 reference

15 March 2018

Fumihiro Urano

3

Fumihiro Urano

1 reference

15 March 2018

author name string

Takashi Honda

1

1 reference

15 March 2018

Mutsumi Murayama

4

1 reference

15 March 2018

Kazuhiko Hayashi

5

1 reference

15 March 2018

Kentaro Yoshioka

8

1 reference

15 March 2018

publication date

1 July 2007

1 reference

15 March 2018

Journal of Gastroenterology and Hepatology

published in

1 reference

15 March 2018

volume

22

1 reference

15 March 2018

issue

7

1 reference

15 March 2018

page(s)

989-995

1 reference

15 March 2018

Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

A proposed system for the nomenclature of hepatitis C viral genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04773.X

10.1111/J.1440-1746.2006.04773.X

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

PubMed ID

17608843

1 reference

15 March 2018